Physician profile
Peter Brian Wittstein
NPI 1104824580
$1,769.88
in general payments reported to CMS, 2019-2025
18 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $45.50 · 2021: $64.16 · 2022: $260 · 2023: $228 · 2024: $388 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $337.28 | 2019-2025 | Clareon, Argos |
| Glaukos Corporation | $210.58 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $201.60 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $162.78 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $142.08 | 2019 | |
| Horizon Therapeutics Plc | $104.13 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $95.76 | 2019-2020 | |
| Alimera Sciences, INC. | $90.18 | 2019 | |
| Apellis Pharmaceuticals, INC. | $78.40 | 2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $70.25 | 2019-2023 | Cequa |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $47.75 | 2019-2023 | |
| Allergan, INC. | $40.55 | 2019-2021 | |
| Harrow Eye, LLC | $40.11 | 2024 | Vevye |
| Johnson & Johnson Surgical Vision, INC. | $36.77 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $17.35 | 2019 | |
| Oyster Point Pharma, INC. | $15.54 | 2024 | Tyrvaya |
| Dompe US, INC. | $14.06 | 2024 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wittstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.